BALPHARMA — Bal Pharma Income Statement
0.000.00%
Last trade - 00:00
- IN₹1.61bn
- IN₹2.92bn
- IN₹3.04bn
- 63
- 32
- 59
- 51
R2019 March 31st | R2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | Interim Report | ARS | ARS | ARS |
Standards: | IAS | — | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2,250 | 1,711 | 2,505 | 2,812 | 3,042 |
Cost of Revenue | |||||
Gross Profit | 1,077 | 873 | 996 | 1,137 | 1,314 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 2,137 | 1,740 | 2,356 | 2,668 | 2,882 |
Operating Profit | 114 | -29.2 | 149 | 144 | 160 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2.02 | -135 | 41 | 91.8 | 47.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | 21.5 | -129 | 47.1 | 57 | 26.2 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 37.9 | -122 | 47.4 | 56.1 | 25.7 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 37.9 | -122 | 47.4 | 56.1 | 25.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2.67 | -8.62 | 3.34 | 3.71 | 1.63 |
Dividends per Share |